Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages

  Volkow, Nora D ^a,b   Wang, Gene Jack ^a   Telang, Frank ^a   Fowler, Joanna S ^c   Alexoff, David ^c   Logan, Jean ^d   Jayne, Millard ^a   Wong, Christopher ^a   Tomasi, Dardo ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amotivation; Brain imaging; Cannabinoid 1 receptors; Midbrain; Nucleus accumbens

Indexed keywords

CANNABIS; DOPAMINE; DOPAMINE 2 RECEPTOR; RACLOPRIDE C 11;

ADULT; ANXIETY; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOPAMINE BRAIN LEVEL; DRUG EFFECT; EMOTIONALITY; FEMALE; HUMAN; IRRITABILITY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULSE RATE; RESTLESSNESS; SELF REPORT; STIMULATION; STRESS; STRIATE CORTEX;

AMOTIVATION; BRAIN IMAGING; CANNABINOID 1 RECEPTORS; MIDBRAIN; NUCLEUS ACCUMBENS;

ADULT; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; EMOTIONS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; METHYLPHENIDATE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; SEVERITY OF ILLNESS INDEX;

EID: 84904962560     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411228111     Document Type: Article

References (80)

1. French ED (1997) delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226(3):159-162.
2. Gessa GL, Melis M, Muntoni AL, Diana M (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341(1):39-44. (Pubitemid 28041196)
3. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85(14):5274-5278.
4. Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science 242(4879):715-723.
5. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191-225.
6. Volkow ND, Wang GJ, Fowler JS, Tomasi D (2012) Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 52:321-336.
7. Drevets WC, et al. (2001) Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49(2):81-96. (Pubitemid 32119502)
8. Laruelle M, et al. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36(7):1182-1190.
9. Volkow ND, et al. (1999) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 291(1):409-415. (Pubitemid 29451617)
10. Bossong MG, et al. (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34(3):759-766.
11. Barkus E, et al. (2011) Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 25(11):1462-1468.
12. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48(1):186-190.
13. 18F-fallypride positron emission tomography study. PLoS ONE 8(7):e70378.
14. Albrecht DS, et al. (2013) Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 128(1-2):52-57.
15. Stokes PR, et al. (2012) History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol 26(1):144-149.
16. 11c]raclopride positron emission tomography study. Biol Psychiatry 71(8):677-683.
17. Martinez D, et al. (2007) Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164(4):622-629. (Pubitemid 46650194)
18. Volkow ND, et al. (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386(6627):830-833. (Pubitemid 27181256)
19. Martinez D, et al. (2005) Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58(10):779-786. (Pubitemid 41677416)
20. Volkow ND, et al. (2007) Profound decreases in dopamine release in striatum in detoxified alcoholics: Possible orbitofrontal involvement. J Neurosci 27(46):12700-12706. (Pubitemid 350127825)
21. Thompson JL, et al. (2013) Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 18(8):909-915.
22. Mizrahi R, et al. (2014) Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39(6):1479-1489.
23. Ducros A, et al. (2007) The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 130(Pt 12):3091-3101. (Pubitemid 350209073)
24. Herning RI, Better WE, Tate K, Cadet JL (2005) Cerebrovascular perfusion in marijuana users during a month of monitored abstinence. Neurology 64(3):488-493. (Pubitemid 40189868)
25. Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S (2012) Cannabis-related stroke: Case series and review of literature. J Stroke Cerebrovasc Dis 21(7):555-560.
26. Wang GJ, et al. (1994) Methylphenidate decreases regional cerebral blood flow in normal human subjects. Life Sci 54(9):PL143-PL146.
27. 11C] raclopride in the human brain. Synapse 16(4):255-262.
28. Volkow ND, et al. (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155(10):1325-1331. (Pubitemid 28471187)
29. Volkow ND, et al. (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. Synapse 43(3):181-187. (Pubitemid 34087672)
30. 2/3 receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology 37(11):2355-2367.
31. Jutras-Aswad D, et al. (2012) Cannabis-dependence risk relates to synergism between neuroticism and proenkephalin SNPs associated with amygdala gene expression: Case-control study. PLoS ONE 7(6):e39243.
32. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
33. Wang GJ, et al. (1997) Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res 3:49-54.
34. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha KK (1991) Extensive and enantioselective presystemic metabolism of dl-threo- methylphenidate in humans. Prog Neuropsychopharmacol Biol Psychiatry 15(2):213-220.
35. Patrick CJ, Curtin JJ, Tellegen A (2002) Development and validation of a brief form of the Multidimensional Personality Questionnaire. Psychol Assess 14(2):150-163. (Pubitemid 34538733)
36. Volkow ND, et al. (1993) Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 34(4):609-613. (Pubitemid 23115661)
37. Friston KJ, et al. (1995) Analysis of fMRI time-series revisited. Neuroimage 2(1):45-53.
38. 11C-methyl]-(-)- cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10(5):740-747.
39. Wang GJ, et al. (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17(9):918-925.
40. Middleton ET, Morice AH (2000) Breath carbon monoxide as an indication of smoking habit. Chest 117(3):758-763. (Pubitemid 30152217)
41. Tzourio-Mazoyer N, et al. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15(1):273-289. (Pubitemid 34852226)
42. Sevy S, et al. (2008) Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 197(4):549-556.
43. Ferré S, Goldberg SR, Lluis C, Franco R (2009) Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 56(Suppl 1):226-234.
44. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17(14):5327-5333.
45. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk? Mol Pharmacol 67(5):1697-1704. (Pubitemid 40594170)
46. Andersson M, et al. (2005) Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 25(37):8432-8438. (Pubitemid 41324729)
47. Giuffrida A, et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2(4):358-363. (Pubitemid 30491279)
48. Maneuf YP, Crossman AR, Brotchie JM (1997) The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 148(1):265-270. (Pubitemid 127445133)
49. Marcellino D, et al. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54(5):815-823.
50. Meschler JP, Clarkson FA, Mathews PJ, Howlett AC, Madras BK (2000) D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in non-human primates. J Pharmacol Exp Ther 292(3):952-959. (Pubitemid 30136587)
51. Meschler JP, Conley TJ, Howlett AC (2000) Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol Biochem Behav 67(3):567-573. (Pubitemid 32103567)
52. Volkow ND, et al. (1998) Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 155(3):344-349. (Pubitemid 28114890)
53. Ersche KD, Jones PS, Williams GB, Robbins TW, Bullmore ET (2013) Cocaine dependence: A fast-track for brain ageing? Mol Psychiatry 18(2):134-135.
54. Geller T, Loftis L, Brink DS (2004) Cerebellar infarction in adolescent males associated with acute marijuana use. Pediatrics 113(4):e365-e370.
55. Mateo I, Infante J, Gómez Beldarrain M, García-Moncó JC (2006) [Cannabis and cerebrovascular disease]. Neurologia 21(4):204-208, Spanish.
56. Wolff V, et al. (2011) Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: A prospective study in 48 consecutive young patients. Stroke 42(6):1778-1780.
57. Ashton JC, Appleton I, Darlington CL, Smith PF (2004) Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J Cardiovasc Pharmacol 44(5):517-519. (Pubitemid 39441689)
58. Rodríguez-Cueto C, et al. (2014) Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br J Pharmacol 171(6):1472-1489.
59. Medina KL, Nagel BJ, Tapert SF (2010) Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Res 182(2):152-159.
60. Sneider JT, et al. (2008) Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers. Eur Neuropsychopharmacol 18(8):612-619.
61. Volkow ND, et al. (1996) Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 67(1):29-38. (Pubitemid 26000713)
62. Bloomfield MA, et al. (2014) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75(6):470-478.
63. Parker C, Clarke K, Gee AD, Gee A, Rabiner E (2006) In vitro characterisation of the high affinity D2/D3 dopamine agonist (+)PhNO. Neuroimage 31(Suppl 2):T29.
64. 11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4] oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48(12):4153-4160.
65. 11C]-(+)-PHNO: Dissection of D3 signal and anatomy. Neuroimage 54(1):264-277.
66. Sokoloff P, et al. (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: Comparison with D2 receptor. Eur J Pharmacol 225(4):331-337.
67. 11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: A positron emission tomography study. J Neurosci 32(4):1353-1359.
68. Heidbreder CA, et al. (2005) The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Brain Res Rev 49(1):77-105. (Pubitemid 40800164)
69. Volkow ND, et al. (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl) 166(3):264-270. (Pubitemid 36384773)
70. Leroy C, et al. (2012) Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: A high-resolution PET study. Addict Biol 17(6):981-990.
71. Campbell I (1976) The amotivational syndrome and cannabis use with emphasis on the Canadian scene. Ann N Y Acad Sci 282:33-36.
72. Koob GF (2008) A role for brain stress systems in addiction. Neuron 59(1):11-34.
73. Hyman SM, Sinha R (2009) Stress-related factors in cannabis use and misuse: Implications for prevention and treatment. J Subst Abuse Treat 36(4):400-413.
74. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: From structure to function. Physiol Rev 78(1):189-225. (Pubitemid 28070979)
75. Bromberg-Martin ES, Matsumoto M, Hikosaka O (2010) Dopamine in motivational control: Rewarding, aversive, and alerting. Neuron 68(5):815-834.
76. Felten A, Montag C, Markett S, Walter NT, Reuter M (2011) Genetically determined dopamine availability predicts disposition for depression. Brain Behav 1(2):109-118.
77. Lynskey MT, et al. (2003) Escalation of drug use in early-onset cannabis users vs cotwin controls. JAMA 289(4):427-433. (Pubitemid 36119962)
78. Bergamaschi MM, et al. (2013) Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem 59(3):519-526.
79. Wang GJ, et al. (1996) MR-PET image coregistration for quantitation of striatal dopamine D2 receptors. J Comput Assist Tomogr 20(3):423-428.
80. Batalla A, et al. (2013) Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings. PLoS ONE 8(2):e55821.